SCHMIEDER, R.E., C. OTT, S.W. TOENNES, P. BRAMLAGE, M. GERTNER, O. DAWOOD, P. BAUMGART, B. O'BRIEN, I. DASGUPTA, G. NICKENIG, J. ORMISTON, M. SAXENA, A.S.P. SHARP, H. SIEVERT, Jindřich ŠPINAR, Zdeněk STÁREK, J. WEIL, U. WENZEL, A. WITKOWSKI and M.D. LOBO. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. Journal of Hypertension. PHILADELPHIA: William and Wilkins, 2018, vol. 36, No 3, p. 680-689. ISSN 0263-6352. Available from: https://dx.doi.org/10.1097/HJH.0000000000001584.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV
Authors SCHMIEDER, R.E. (276 Germany, guarantor), C. OTT (276 Germany), S.W. TOENNES (276 Germany), P. BRAMLAGE (276 Germany), M. GERTNER (840 United States of America), O. DAWOOD (840 United States of America), P. BAUMGART (276 Germany), B. O'BRIEN (826 United Kingdom of Great Britain and Northern Ireland), I. DASGUPTA (826 United Kingdom of Great Britain and Northern Ireland), G. NICKENIG (276 Germany), J. ORMISTON (554 New Zealand), M. SAXENA (826 United Kingdom of Great Britain and Northern Ireland), A.S.P. SHARP (826 United Kingdom of Great Britain and Northern Ireland), H. SIEVERT (276 Germany), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Zdeněk STÁREK (203 Czech Republic), J. WEIL (276 Germany), U. WENZEL (276 Germany), A. WITKOWSKI (616 Poland) and M.D. LOBO (826 United Kingdom of Great Britain and Northern Ireland).
Edition Journal of Hypertension, PHILADELPHIA, William and Wilkins, 2018, 0263-6352.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.209
RIV identification code RIV/00216224:14110/18:00103132
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1097/HJH.0000000000001584
UT WoS 000429317500029
Keywords in English renal denervation; treatment-resistant hypertension; ultrasound; WAVE IV
Tags 14110115, 14110211, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 17:22.
Abstract
Objectives: The aim of this double-blind, randomized, sham-controlled study was to verify the blood pressure (BP)-lowering efficacy of externally delivered focused ultrasound for renal denervation (RDN). Background: Nonrandomized, first proof-of-concept study and experimental evidence suggested that noninvasive techniques of RDN emerged as an alternative approach of RDN to invasive technologies. Methods: WAVE IV, an international, randomized (1 : 1) sham-controlled, double-blind prospective clinical study, was prematurely stopped. Patients were enrolled if office BP was at least 160 mmHg and 24-h ambulatory BP was at least 135 mmHg, while taking three or more antihypertensive medications. The treatment consisted of bilateral RDN using therapeutic levels of ultrasound energy and the sham consisted of bilateral application of diagnostic levels of ultrasound energy. Results: In the 81 treated patients neither changes in office BP at 12 and 24 weeks, nor changes in 24-h ambulatory BP at 24-week follow-up visit differed between the two groups significantly. Of note, no safety signal was observed. Adherence analysis disclosed full adherence in 77% at baseline and 82% at 6 months' follow-up visit. Post hoc analysis revealed that stricter criteria for stabilization of BP at baseline were associated with a numerically greater change in 24-h ambulatory BP in the RDN group than in the sham group. Conclusion: Our data did not prove that antihypertensive efficacy of the externally delivered focused ultrasound for RDN was greater than the sham effect. Stabilization of BP at baseline was identified as an important determinant of BP changes.
PrintDisplayed: 6/9/2024 06:05